Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 5/20 | 0.52 |
| ▸ | CDK9 | P50750 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949785 | 0.88 | CCNT1 (0.54) | CCNT1CDK9CDK2CCNA2CCNE2 | |
| SCHEMBL6949781 | 0.85 | CCNT1 (0.52) | CCNT1CDK9CDK2CCNA2CCNE2 | |
| SCHEMBL6952834 | 0.85 | CCNT1 (0.52) | CCNT1CDK9CDK2CCNA2CCNE2 | |
| SCHEMBL7501550 | 0.83 | CCNT1 (0.49) | CCNT1CDK9CDK2CCNA2CCNE2 | |
| Enmd-981693 SCHEMBL608128 | 0.82 | CCNE2 (0.69) | CDK2CCNE2CDK4CCND1CCNE1 | |
| Enmd-981693 SCHEMBL29350364 | 0.82 | CCNE2 (0.69) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8476465 | 0.82 | CCNE2 (0.48) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL7500940 | 0.82 | CCNT1 (0.46) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL7507368 | 0.81 | CCNT1 (0.42) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL6956384 | 0.81 | CCNT1 (0.46) | CCNT1CDK9CDK2CCNA2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1155595-C | Substituted pyrroles as antiproliferative agents for the treatment of cancer | - | 2004-06-30 | — | — | CN | claimed |
| EP-1224181-B1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2003-12-03 | — | — | EP | claimed |
| US-6559164-B1 | These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. | HOFFMANN-LA ROCHE INC. | 2003-05-06 | — | — | US | claimed |
| CN-1378545-A | Substituted pyrroles as antiproliferative agents for treatment of cancer | HOFFMANN LA ROCHE (CH) | 2002-11-06 | — | — | CN | claimed |
| EP-1224181-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | claimed |
| EP-1224181-B1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2003-12-03 | — | — | EP | disclosed |
| US-6559164-B1 | These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. | HOFFMANN-LA ROCHE INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1224181-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |